Duchenne Muscular Dystrophy Pipeline Expands with 75+ Therapies Across Clinical and Preclinical Stages, Finds DelveInsight

Duchenne Muscular Dystrophy Pipeline Expands with 75+ Therapies Across Clinical and Preclinical Stages, Finds DelveInsight
DelveInsight's "Duchenne Muscular Dystrophy Pipeline Insight 2025" report delivers extensive insights into more than 75 companies and 75+ investigational therapies shaping the Duchenne Muscular Dystrophy pipeline landscape. The report examines detailed profiles of Duchenne Muscular Dystrophy pipeline drugs, encompassing both clinical-stage and preclinical candidates. It also evaluates the Duchenne Muscular Dystrophy therapeutic landscape based on product type, stage of development, route of administration, and molecule category. Additionally, the report highlights discontinued or inactive pipeline candidates within this therapeutic area.

Explore our latest breakthroughs in Duchenne Muscular Dystrophy research. Discover more about our innovative pipeline today! @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Duchenne Muscular Dystrophy Pipeline Report
• On January 26, 2026 - Cumberland Pharmaceuticals initiated a clinical study with an optional open-label extension to evaluate the safety, pharmacokinetics (PK), and efficacy of two oral doses of ifetroban in individuals with DMD. Participants who satisfy the inclusion criteria and do not meet exclusion requirements will receive either oral ifetroban or placebo once daily for a period of 12 months. Enrolled participants will be assigned to one of three treatment groups: low-dose ifetroban, high-dose ifetroban, or placebo. Each dosing group will include eight participants with early-stage DMD-associated cardiomyopathy (LVEF >45%) and eight participants with more advanced cardiac disease (LVEF 35-45%), as treatment responses may vary depending on the degree of cardiac involvement. Pharmacokinetic evaluations will assess both first-dose exposure and steady-state levels, while all treated participants will undergo continuous safety monitoring.
• On January 21, 2026 - Italfarmaco initiated a study evaluating Givinostat in Duchenne Muscular Dystrophy patients who had previously participated in earlier Givinostat clinical trials.
• On January 09, 2026 - Santhera Pharmaceuticals launched a study involving participants who had completed earlier studies with vamorolone and had continued receiving the therapy through special access programs, including the Compassionate Use Program (CUP), Named Patient Program (NPP), or Expanded Access Protocol (EAP). Under the new Guardian protocol, participants will continue vamorolone treatment. The primary aim of the study is to assess the long-term safety of vamorolone therapy in boys with Duchenne Muscular Dystrophy, particularly regarding vertebral fractures. Secondary objectives include evaluating safety outcomes related to non-vertebral fractures, cataracts, delayed puberty, overall safety, and functional performance in both ambulatory and non-ambulatory patients.
• On January 05, 2026 - Hoffmann-La Roche initiated a study designed to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody.
• On January 05, 2026 - Satellos Bioscience Inc. announced the launch of a global Phase IIa trial evaluating SAT-3247 in ambulatory DMD patients aged ≥7. This randomized, double-blind, placebo-controlled trial will investigate two doses of SAT-3247 administered in a weekday dosing regimen for 12 weeks. The study aims to determine the optimal dosage, safety, tolerability, and early efficacy signals. One dose of SAT-3247 along with placebo will be evaluated in the United States and Canada, while two doses plus placebo will be investigated in the United Kingdom, European Union, Serbia, and Australia.
• On January 02, 2026 - Pfizer initiated a clinical study evaluating the safety and efficacy of gene therapy in boys diagnosed with Duchenne Muscular Dystrophy. The study follows a randomized, double-blind, placebo-controlled design, where approximately two-thirds of participants will receive gene therapy. The remaining one-third assigned to the placebo arm will have the opportunity to receive gene therapy treatment beginning in the second year of the study.
• DelveInsight's Duchenne Muscular Dystrophy pipeline analysis highlights a dynamic and competitive development landscape, with more than 75 active companies currently working on over 75 investigational therapies targeting Duchenne Muscular Dystrophy.
• Key companies involved in Duchenne Muscular Dystrophy drug development include Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Daiichi Sankyo, ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and others.
• Prominent Duchenne Muscular Dystrophy therapies under development include Vamorolone, Sevasemten 10 mg, Givinostat, DS-5141b, SGT-003, PF-06939926, NS-089/NCNP-02, among others.

Stay updated with the latest developments in Duchenne Muscular Dystrophy treatments. Download the report to receive timely insights and be part of the transformation in musculoskeletal care @ Duchenne Muscular Dystrophy Clinical Trials Assessment - @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Duchenne Muscular Dystrophy Overview
Duchenne Muscular Dystrophy (DMD) is a rare and inherited progressive neuromuscular condition caused by mutations in the DMD gene, which encodes dystrophin a protein essential for maintaining the structural stability of muscle cells. In the absence of dystrophin, muscle fibers become fragile and susceptible to damage, resulting in progressive muscle degeneration and weakness. The condition predominantly affects boys, with symptoms typically appearing between 2 and 5 years of age. Early indicators often include difficulty running, climbing stairs, frequent falls, enlarged calf muscles, and delayed motor development. As the disease progresses, it impacts skeletal muscles as well as the heart (cardiomyopathy) and respiratory muscles, gradually limiting mobility. Most patients require wheelchair assistance during early adolescence and may require respiratory and cardiac support later in life.

Duchenne Muscular Dystrophy Emerging Drugs
Vamorolone: Santhera
Vamorolone is a first-in-class therapeutic candidate that binds to the same receptors as corticosteroids while altering downstream receptor activity. This mechanism may help separate therapeutic benefits from many of the safety issues typically associated with steroid therapy. As a result, vamorolone has the potential to become an effective alternative to traditional corticosteroids, which are currently the standard treatment for pediatric and adolescent DMD patients. Given the significant side effects linked with long-term high-dose corticosteroid use, there remains a substantial unmet need for safer therapies that improve patient quality of life. On September 2, 2020, Santhera exercised its option to obtain global rights to vamorolone for Duchenne Muscular Dystrophy and other potential indications. Santhera and ReveraGen previously planned to complete a rolling NDA submission to the U.S. FDA in June 2022.

Givinostat: Italfarmaco
Givinostat is a histone deacetylase inhibitor (HDACi) and represents a leading investigational therapy being developed for both Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). By targeting downstream pathogenic processes associated with genetic defects, Givinostat may provide therapeutic benefits across a broad DMD and BMD patient population. Its mechanism aims to counteract disease-driving molecular events across various muscle groups.

Pamrevlumab: FibroGen
Pamrevlumab is a first-in-class monoclonal antibody developed by FibroGen that targets connective tissue growth factor (CTGF). CTGF plays a key role in fibrotic and proliferative disorders characterized by excessive tissue scarring that may ultimately lead to organ dysfunction. Pamrevlumab is progressing toward Phase III clinical development for conditions such as idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, where it has received Orphan Drug Designation (ODD). The therapy is also currently being investigated in a Phase II trial for Duchenne Muscular Dystrophy.

The Duchenne Muscular Dystrophy Pipeline Report Provides Insights into
The report delivers in-depth insights into companies actively developing therapies for Duchenne Muscular Dystrophy, including a consolidated overview of each company's pipeline portfolio.
It evaluates therapeutic candidates across early-stage, mid-stage, and late-stage development phases for Duchenne Muscular Dystrophy treatment.
Companies working in the Duchenne Muscular Dystrophy pipeline are pursuing targeted therapeutic strategies, including both active and inactive (dormant or discontinued) development programs.
The report categorizes drugs under development according to development stage, route of administration, molecular type, target receptor, treatment strategy (monotherapy or combination therapy), and mechanism of action.
It also provides comprehensive insights into collaborations, licensing agreements, company-to-company partnerships, academic partnerships, and financing activities that could influence the future growth of the Duchenne Muscular Dystrophy market.

Learn more about Duchenne Muscular Dystrophy drug opportunities through our innovative research and development insights @ Duchenne Muscular Dystrophy Unmet Needs - @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Duchenne Muscular Dystrophy Companies
Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Daiichi Sankyo, ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and others.

Duchenne Muscular Dystrophy Pipeline Therapeutic Assessment by Route of Administration
• Oral
• Intravenous
• Subcutaneous

Duchenne Muscular Dystrophy Products Categorized by Molecule Type
• Small molecules
• Cell therapies
• Peptides
• Polymers
• Gene therapies

Discover the newest innovations in Duchenne Muscular Dystrophy treatment by visiting our website and learn how emerging research is reshaping the future of musculoskeletal healthcare @ Duchenne Muscular Dystrophy Market Drivers and Barriers, and Future Perspectives - @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Duchenne Muscular Dystrophy Pipeline Report
• Coverage - Global
• Duchenne Muscular Dystrophy Companies - Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Daiichi Sankyo, ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and others.
• Duchenne Muscular Dystrophy Therapies - Vamorolone, Sevasemten 10 mg, Givinostat, DS-5141b, SGT-003, PF-06939926, NS-089/NCNP-02, and others.
• Therapeutic Assessment by Product Type - Monotherapy, Combination Therapy, Mono/Combination
• Therapeutic Assessment by Development Stage - Discovery, Preclinical, Phase I, Phase II, Phase III

For a comprehensive overview of our latest research insights and future development strategies, explore the complete Duchenne Muscular Dystrophy pipeline report on our website @ Duchenne Muscular Dystrophy Drugs and Companies - @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
• Introduction
• Executive Summary
• Duchenne Muscular Dystrophy: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Duchenne Muscular Dystrophy - DelveInsight's Analytical Perspective
• Late-Stage Products (Phase III)
• Delandistrogene moxeparvovec: Roche
• Drug profiles in the detailed report...
• Mid-Stage Products (Phase II)
• SRP-5051: Sarepta Therapeutics
• Drug profiles in the detailed report...
• Early-Stage Products (Phase I/II)
• WVE N531: Wave Life Sciences
• Drug profiles in the detailed report...
• Early-Stage Products (Phase I)
• EDG 5506: Edgewise Therapeutics
• Drug profiles in the detailed report...
• Inactive Products
• Duchenne Muscular Dystrophy Key Companies
• Duchenne Muscular Dystrophy Key Products
• Duchenne Muscular Dystrophy - Unmet Needs
• Duchenne Muscular Dystrophy - Market Drivers and Barriers
• Duchenne Muscular Dystrophy - Future Perspectives and Conclusion
• Duchenne Muscular Dystrophy Analyst Views
• Duchenne Muscular Dystrophy Key Companies
• Appendix
• About Us

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.